Led by Washington University School of Medicine in St. Louis and other institutions around the world, the Clinical Proteomic Tumor Analysis Consortium has completed a deep analysis of the proteins driving cancer across multiple tumor types, information that can’t be assessed by genome sequencing alone. Understanding how proteins operate in cancer cells raises the prospect of new therapies.